Introduction
Tuberculosis (TB) is an epidemic disease caused by the Mycobacterium tuberculosis (Mtb) complex. According to the World Health Organization 1 , TB resulted in the death of 1.5 million people from a total of 9.0 million infection cases in 2013. Of those cases, multidrug-resistant TB (MDR-TB) is estimated to represent half a million cases and the actual number of MDR-TB cases diagnosed has tripled between 2009 and 2013. An estimated 9% of people with MDR-TB have TB classified as extensively drug-resistant TB (XDR-TB). The treatment regimens for these differing forms of TB are highly complex and there are five classes of drug groups used to treat TB 2 . The common first line drugs are classified as Group 1. Oral and include: isoniazid (H/Inh), rifampicin/rifampin (R/Rif), pyrazinamide (Z/Pza), ethambutol (E/Emb), rifapentine (P/Rpt) or rifabutin (Rfb). The current standard for treating drug sensitive TB involves a quadruple drug combination: two months of four drugs (Inh, Rif, Pza and Emb) in the intensive phase followed by four months of Inh plus Rif in the continuation stage. It is commonly believed that resistance develops during these long treatment times thereby requiring the use of second and third line TB drugs. Thus, there is a great need to identify drugs for treating drug-resistant and drugsensitive TB in a shorter time span. Mtb GlgE is an essential enzyme which catalyzes the synthesis of cytoplasmic α-glucan by transferring maltose-1-phosphate (M1P) (Fig. 1) to a growing α-1,4-glucan chain. The pathway begins with isomerization of trehalose by TreS into maltose. The latter is phosphorylated by Pep2 kinase to form maltose-1-phosphate (M1P) which is utilized by GlgE to produce linear α-1,4-glucan. Inhibiting GlgE results in accumulation of M1P which causes rapid death of Mtb in vitro and in mice 3 . We have reported the first inhibitors of Mtb respectively. To identify more potent inhibitors we have embarked on a structure-based inhibitor study which utilizes X-ray crystallography to reveal key binding interactions between GlgE and our target ligands. We anticipate these studies will inform improved inhibitor designs. However, an obstacle to achieving this goal is that Mtb GlgE crystalizes poorly/slowly and crystals diffract to afford lower resolution Xray data (e.g. 3.2 -4.0 Å) 6 . To obtain X-ray structures with higher throughput and resolution, Sco GlgEI-V279S was designed as a readily crystallized homologue of Mtb GlgE that possesses the same active site topology as Mtb GlgE 6 . This approach has been highly successful and has generated X-ray complexes of both MCP and 2,5-dideoxy-3-O-α-Dglucopyranosyl-2,5-imino-D-mannitol 6 , and now, 2-deoxy-2,2-difluoro-α-maltosyl fluoride (α-MTF, 5) (Fig. 1) 8 . That study is notable as the E423A point mutation was required to prevent hydrolysis of the β-maltosyl enzyme intermediate. In the structure described here, Sco GlgEI-V279S contains the general base Glu423 and yet α-MTF co-crystalized with enzyme fully intact and showed no formation of a covalent glycosyl-enzyme intermediate. Based on previously reported studies involving homologous 2-deoxy-2,2-difluoroglycosides 9, 10 , the lower reactivity of the trifluoride 5 can be most readily explained by reactivity differences that result from the lower leaving group ability of the C1' fluorine. Analysis of the X-ray complex and comparison with the complementary MCP probe reveals the hydrogen bonding interactions present within the inhibitor-enzyme complex just prior to formation of the glycosyl enzyme intermediate.
Comparison of these structures also reveals the role of the M1P phosphate in orienting the -1 site sugar into a reactive geometry. We also outline a synthesis of α-MTF (5) which was accessed from peracetylated 2,2-difluoro-α-maltosyl fluoride 2. These targets were accessed in a single step, via the use of Selectfluor ® on peracetylated 2-fluoro-maltal 1 10 .
Results and discussion

Synthesis of 2,2-difluoro-α/β-D-maltosyl fluorides (2, 3)
2-Deoxy-2,2-difluoro-α/β-maltosyl fluorides were accessed from the peracetylated 2-fluoro-maltal 1, 10 Please do not adjust margins
Please do not adjust margins at -20 °C to afford an α/β mixture of peracetylated 2,2-difluoromaltosyl fluorides with a modest 12% yield. Glycosides 2 and 3 were deprotected by using NH 3 -methanol to afford 2-deoxy-2,2-difluoro-α-maltosyl fluoride (5) and 2-deoxy-2,2-difluoro-β-maltosyl fluoride (6), respectively. The anomeric configuration was assigned by the H-F coupling constants as shown in Scheme 2.
Enzyme inhibition assay of α-MTF
Recombinant Sco GlgEI-V279S is produced in E. coli and purified using the methods detailed previously 5 . Inhibition of this enzyme using 2 α-MTF (5) and 2-deoxy-2,2-difluoro-β-maltosyl fluoride (6) was performed by coupling GlgEI-V279S activity with the commercially available EnzCheck ® Phosphate
Assay Kit (Life Technologies) 4 . The compounds showed no inhibitory activity below 10 mM concentration.
Enzyme substrate assay for α-MTF
As an orthogonal qualitative assessment, MALDI-MS was performed to evaluate α-MTF incorporation into maltooligosaccharides via Sco GlgE-V279S and compared to a series of controls (Fig S-1, Supporting Information,) . The results indicate α-MTF was not a substrate for GlgE.
X-ray crystal structure of the Sco GlgEI-V279S-α-MTF complex
A complex of Sco GlgEI-V279S and α-MTF was co-crystallized and the structure solved using the Sco GlgE-V279S-MCP structure as a model for rigid body refinement (RCSB ascension number 4U31), Table 1 . Inspection of the initial |F o -F c | map exhibited clear density for the maltosyl unit of the α-MTF (Fig   2A) , but no continuous density was observed between the nucleophile, Asp394, and the α-MTF, indicating the absence of a covalent intermediate. NMR and mass spectrometry experiments produced negative results for the GlgEI-V279S catalyzed transfer reaction using α-MTF, which suggests that Sco GlgEI-V279S cannot undergo a nucleophilic attack on α-MTF. Difference density is observed for the 2,2-difluoromethylene group at C2' with the final model exhibiting a pair of hydrogen bonded interactions between the difluoromethylene moiety and the side chain of Arg392 (Fig 2B  and 2C ). The nucleophile Asp394 is forming a non-covalent bond with the equatorial fluorine at C2'. This suggests that Asp394 may be protonated in this form. Considering the role of Asp394 as a nucleophile in the catalytic reaction, an intriguing alternative interpretation is that this interaction may represent a halogen bond between the carboxylate of Asp394 and the fluorine at C2'.
Residue Glu423, proposed to function as a general acid to protonate the phosphate leaving group, is forming a 3.3 Å hydrogen bond with atom F1 since it is expected to be protonated during the first step of catalysis. Similar to the case of the interaction between Asp394 and the fluorine at C2', the protonation state of Glu423 is unknown and the interaction with F1 may represent a halogen bond. Additionally, interactions observed between the protein and the second glucosyl moiety of the α-MTF are consistent with those observed in other GlgE structures (not shown).
After preparing α-MTF we evaluated its ability to serve as a substrate for Sco GlgEI-V279S. We found, in the absence of a maltosyl-donor Sco GlgEI-V279S is able hydrolyze maltooligosaccharides and rearrange them into both longer Please do not adjust margins
Please do not adjust margins and shorter polymers via a maltosyl-mixing (transglycosylation) process 7 . That reaction was performed, as a control, in order to determine the relative abundance of certain maltooligosaccharide sizes that would be observed if α-MTF could not be utilized as a substrate. A variety of maltooligosaccharide sizes were observed from the smallest four maltose units (M4), up to the largest twelve maltose units (M12) (Fig S-1B , Supporting Information). The relative intensities suggest that the Sco GlgE-V279S prefers chain lengths of six maltose units (M6) and eight maltose units (M8) (~2:1 ratio) as acceptors rather than the larger maltooligosaccharides such as ten maltose units (M10) (~7:1) and twelve maltose units (M12) (~66:1). The production of M4, which appears in an approximate ratio of 12:1 with M6, is likely the result of the hydrolysis of a maltosyl unit from the M6.
It had been shown previously that that M1F could be used as an efficient maltosyl-donor for both the wild-type Mtb and Sco GlgEI 7 . Therefore, this glycosyl fluoride was used as a control substrate for these tests (Fig S-1 , Supporting Information). Using the M1F as a donor substrate results in a mass increase of 320 Daltons. The relative ratios of the maltooligosaccharides compared to the M6 changed significantly compared to the control reaction of the ScoGlgE-V279S and M6 (Fig S-1C , Supporting Information). Significantly more M8 was produced (~1.1:1) in addition to M10 (~3:1) and M12 (10:1). Again, some M4 was produced (~14:1 in slightly lower amounts than the control, and is likely the result of the background maltosyl-mixing process observed in the control reactions performed without M1F. In addition, M14 was produced (~59:1), which did not occur in the control reaction. Whereas the control reaction represented the maltosyl mixing process, the reaction with the M1F maltosyl donor suggests authentic elongation of the polysaccharide. Any maltooligosaccharides generated by the incorporation of the α-MTF would result in a mass increase of approximately 344 Daltons per unit as a result of the presence of the difluoro substitution at C2'. This is in contrast to the M1F, where an addition would change the mass by 324 Daltons; the incorporation of single maltosyl unit from the M1F. Reactions using the α-MTF as a substrate do not show incorporation of difluoride into M6 (Fig S-1D, Supporting Information) . The spectrum observed from the α-MTF reaction is characteristic of the control reaction containing only M6 and GlgE. Indeed, the observed ion ratios are similar to that observed in the M6 control reaction further suggesting that the α-MTF also does not inhibit the maltosyltransfer reaction. However, most obvious, is the lack of the additional 20 Daltons that would accompany either the incorporation of the α-MTF via elongation or as a result of maltosyl-mixing. Taken together, these data suggest that the α-MTF cannot be used as a maltosyl-donor for GlgE activity and does not inhibit the activity of GlgE either.
The structure of the Sco GlgEI-E423A covalently modified using α-MDF was recently published showing that 2-deoxy-2-fluoroglycosyl fluorides react with this general baseinactivated variant enzyme 8 . In an attempt to form a stable non-covalent complex with a fully active enzyme, we crystallized a complex of chimeric Sco GlgEI-V279S with α-MTF. In contrast to the α-MDF, the α-MTF complex structure described here lacks contiguous difference density between the Asp394 nucleophile and α-MTF, suggesting that α-MTF has not undergone nucleophilic attack by the enzyme. This is likely the result of the difluoromethylene center at the C2' position being highly electron withdrawing and thus strongly destabilizing the putative oxocarbenium transition state and making the fluorine at C1' a very poor leaving group and thereby inhibiting the enzymatic reaction. This result suggests that α-MTF, and perhaps other 2-deoxy-2,2-difluoro-glycosyl fluorides, can be used as non-hydrolysable substrate analogues for glycoside hydrolases. Therefore, the Sco GlgEI-V279S-α-MTF complex can be used to infer key molecular interactions between authentic substrate and GlgEI-V279S
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Please do not adjust margins immediately prior to nucleophilic attack without the need to disrupt catalytic residues. Further, comparison of the structure with other substrate analogues reveals how changes in analogue structure effect the organization of the active site residues and the conformation of the bound ligand.
Since α-MTF does not react with the GlgEI nucleophile in the α-MTF crystal structure, important information can be obtained and used in the design of inhibitors targeting Sco GlgEI and presumably the homologous Mtb GlgE. The presence of the difluoromethylene center on the C2' is resolved and forms a bidentate hydrogen bonding interaction with Arg392 in the active site. Despite the addition of two fluorine atoms at the C2' position, only minor alterations in the active site were observed in comparison Sco GlgEI-V279S-MCP complex, Fig. 3 6 .
This suggests that the GlgE active site tolerates the inclusion of hydrogen bond acceptors at the axial C2' position and may indicate the site is tolerant of other modifications required to make future inhibitors more drug-like.
Comparison of the Sco GlgEI-V279S-MCP 6 and Sco GlgEI-V279S-α-MTF at the -2 sugar binding subsite revealed identical patters of hydrogen bonding within the active site (not shown). It was also notable that the Ser279 side chain forms a hydrogen bonding interaction with the endocyclic O5 atom in the -2 sugar binding subsite in both structures (also not shown). This observation reinforces our belief that the serine in the active site of Mtb GlgE is important for substrate recognition and would therefore affect inhibitor binding as well. Comparison of the Sco GlgEI-V279S-α-MTF (Fig. 3A) and Sco GlgEI-V279S-MCP (Fig. 3B ) -1 sugar binding subsite site revealed more interesting changes. We noted identical patterns of potential hydrogen bonding for the Gln324 side chain with the O6'(H) (3.0 Å and 2.9 Å, measured between heteroatoms, respectively). Similarly, the Asp394 side chain oxygen shows possible hydrogen bonding with O6'(H) (2.8 Å measured between heteroatoms in both structures). The Asn395 side chain nitrogen is within similar hydrogen bonding distance of the endocyclic O5' atom (2.6 Å and 2.8 Å, respectively) in both structures as well. As mentioned previously, the α-MTF forms a bidentate hydrogen bonding interaction with the NH 1 and NH 2 side chain groups of Arg392 conformation. The flatting out of the endocyclic oxygen has been predicted to be part of a necessary transition state geometry required during catalysis. Thus, it can also be concluded that the additional binding interactions present in the MCP complex may be required to achieve the distorted, transition-state-like geometry observed in the MCP complex.
As mentioned previously, a hydrogen bonding interaction is noted between putative proton donor Glu423 and the C1'F in α-MTF at 3.3 Å measured between heteroatoms. These interactions provide evidence that Glu423 functions as a proton donor in the first catalytic step leading to the glycosyl enzyme intermediate.
Experimental Crystallization of the Sco GlgEI-V279S-α-MTF
The Sco GlgEI-V279S concentrated to 8.0 mg/mL (0.1% Abs value of 1.526) was used for crystallization experiments. 
Diffraction experiments
X-ray diffraction experiments were carried out at the LS-CAT beamline at the Advanced Photon Source of Argonne National Labs, Argonne, IL. The Sco GlgEI-V279S-α-MTF structure was elucidated using diffraction data collected at a wavelength of 1.07819 Å. Diffraction data were integrated and scaled using HKL3000 12 .
Structural Determination of the Sco GlgE-V279S-α-MTF
The Sco GlgEI-V279S-α-MTF structure used the Sco GlgEI-V279S-MCP structure (RCSB ascension number 4U31) as a model for rigid body refinement. Rigid body refinement, simulated annealing, positional and B-factor refinements were performed using PHENIX 13, 14 . Manual refinement of the structure was performed using COOT 15 . The α-MTF ligand and ligand restraints were generated using eLBOW software in PHENIX 16 . Validation of the Sco GlgEI-V279S-α-MTF was performed using Molprobity 17 .
General methods
All starting material compounds were bought from Acros organics or Aldrich. Unless specified all the reaction were done under nitrogen atmosphere. Reactions were monitored by Thin-layer chromatography (TLC silica gel 60 F 254 ) and spots were observed by dipping in 5% H 2 SO 4 , Ceric ammonium molybdate (CAM) or p-Anisaldehyde and heated. All solvents used for reaction were purchased from Fisher, purified and dried by distillation and other standard procedures, and solvents for column chromatography are used as purchased. Purifications of compounds were done by liquid Please do not adjust margins
Please do not adjust margins chromatography (silica gel column chromatography) with silica (porosity 60Å, 230-400 mesh) from sorbent technology. 1 H NMR, 13 C NMR, G-COSY and HMQC spectra were carried out using a Bruker Avance III 600 or Inova 600 spectrometers in Fourier transformation mode. 1 H-NMR and 13 C-NMR were referenced to residual CDCl 3 peak at 7.27 ppm, and 77.16 ppm respectively. 19 F-NMR spectra were obtained by using VXRS400
and Gemini200 spectrometer and referenced to CFCl 3 (0.0 ppm). High resolution mass spectroscopy (HRMS) was performed on a micro mass Q-TOF2 instrument. ,3',4',6'-Tetra-O-acetyl-α-D-glucopyranosyl-(1,4)-3,6-di-Oacetyl-2-deoxy-2,2-difluoro-α/β-D-glucosyl  fluoride/hydroxide (2, 3, 4) Condition a. The starting material 2-fluoro maltal (1) (36.1 mg, 62.5 µmol) was dissolved in CH 3 
2'
Inhibition studies
The procedure for this assay is previously reported. 4 The assay is performed at room temperature using a Spectra max 340PC microplate reader and a 96 well transparent plate. 
MS labeling studies
A stock solution of 2-deoxy-2,2-difluoro-α-maltosyl fluoride (5) at a concentration of 130 µM was added to a solution of 13 µM Sco GlgEI-V279S (1 mg/mL) in ammonium acetate pH 7.0. The reaction mixture was incubated at room temperature for 2 h. The excess of compound 5 was removed using 3 buffer exchange steps into a 10 mM ammonium acetate pH 7.0 buffer using ultrafiltration. The protein samples were digested with sequencing-grade trypsin using standard protocols (Promega). Determination of peptide mass was carried out by MALDI-MS using a Bruker UltafleXtreme (Bruker Daltonics). The mass of only the native protein fragment was observed (m/z = 1695.9020).
Sco-GlgE-V279S maltooligosaccharide extension using M1F and α-MTF as substrates
Enzymatic reactions were carried out in 50 μL reactions containing 50 nM of GlgE and 1 mM maltohexaose in a reaction solution containing 20 mM sodium acetate at pH 7.5. Four reactions were performed: a control containing only maltohexaose (M6), a control reaction of only GlgE and M6, a reaction containing GlgE, M6, and 1 mM of M1F, and a final reaction containing GlgE, M6 and 1 mM of the α-MTF.
Determination of maltooligosaccharide size using MALDI-MS
One μL aliquots of each reaction were removed after 10 minutes and the reactions quenched using 19 μL of a saturated
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Please do not adjust margins DHB (2,5-dihydroxybenzoic acid) matrix solution dissolved in acetonitrile/water (1:1, v/v) with 0.1% trifluoroacetic acid (TFA). Determination of maltooligosaccharide elongation was carried out in positive-ion reflectron mode using an UltrafleXtreme MALDI-TOF/TOF mass spectrometer (Bruker).
Conclusions
In summary, we have synthesized 2-deoxy-2,2-difluoro-α-matosyl fluoride (2) , and the epimeric 2-deoxy-2,2-difluoro-β-maltosyl fluoride (3) in a single step from peracetylated 2-fluoro-maltal 1 using Selectfluor ® . Trifluoride 2 was successfully deprotected to afford α-MTF, a non-hydrolysable substrate mimic of M1P. Enzymatic, mass spectral, and 19 F-NMR studies with Sco GlgEI-V279S showed no inhibition at concentrations below 10 mM, no labeled protein, and no fluoride release, respectively. The lack of significant inhibition by α-MTF suggests both that the phosphate and equatorial OH moieties in M1P contribute significantly to substrate binding. This data also suggest that the role of the -2 sugar binding subsite is primarily shape recognition. The unreactive nature of α-MTF supports the notion that Sco GlgEI-V279S likely proceeds though a late dissociate transition state, destabilized by the 2,2-fluoromethylene modification, in the first step of the enzymatic reaction. 18 The X-ray structure of the Sco GlgEI-V279S in complex with α-MTF was solved. These results also illustrate how Sco GlgEI-V279S can be used in lieu of Mtb GlgE to rapidly probing important protein-ligand interactions. In these studies α-MTF was found to be useful as probe molecule for interrogating key active site binding interactions. When these interactions are compared in conjunction with the MCP complex, the role of the phosphate in M1P on binding conformation can be inferred. The combined structural data from the α-MTF and MCP complexes will inevitably be helpful in the design potent inhibitors of the homologue Mtb GlgE enzyme, a genetically validated target for TB treatment.
